ERBB2 and breast cancer: In this phase I study, QLNC120 was well tolerated at doses up to 1250 mg daily with clinical activity at doses ranging from 450 mg to 1000 mg in heavily pretreated patients with HER2 overexpressing advanced breast cancer.